Cognitive impairment in multiple sclerosis - Recent advances and future prospects

European Neurological Review

Volumn 5, Issue 1, 2010, Pages 69-72

  Langdon, Dawn ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cognitive impairment; Cognitive test batteries; Executive functions; Memory loss; Multiple sclerosis; Rivastigmine

Indexed keywords

EID: 84858267951     PISSN: 17583837     EISSN: 17583845     Source Type: Journal    
DOI: 10.17925/ENR.2010.05.01.69     Document Type: Article

References (51)

1. Charcot JM, Lessons sur les maladies du système nerveux à la Salpetrière, Paris: Delahaye, 1873.
2. Richardson JT, Robinson A, Robinson I, Cognition and multiple sclerosis: a historical analysis of medical perceptions, J Hist Neurosci, 1997;6(3):302-19.
3. Chiaravalloti ND, DeLuca J, Cognitive impairment in multiple sclerosis, Lancet Neurol, 2008;7:1139-51.
4. Potagas C, Giogkaraki E, Koutsis G, et al., Cognitive impairment in different MS subtypes and clinically isolated syndromes, J Neurol Sci, 2008;267(1-2):100-6.
5. Amato MP, Zipoli V, Goretti B, et al., Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort, J Neurol, 2006;253(8):1054-9.
6. Amato MP, Zipoli V, Portaccio E, Multiple sclerosisrelated cognitive changes: a review of cross-sectional and longitudinal studies, J Neurol Sci, 2006;245(1-2):41-6.
7. Amato MP, Ponziani G, Siracusa G, Sorbi S, Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years, Arch Neurol, 2001;58(10):1602-6.
8. Rao SM, Leo GJ, Ellington L, et al., Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning, Neurology, 1991;41(5):692-6.
9. Langdon DW, Thompson AJ, Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome, Mult Scler, 1999;5(2):94-100.
10. Kalmar JH, Gaudino EA, Moore NB, et al., The relationship between cognitive deficits and everyday functional activities in multiple sclerosis, Neuropsychology, 2008;22(4):442-9.
11. Schultheis MT, Weisser V, Ang J, et al., Examining the relationship between cognition and driving performance in multiple sclerosis, Arch Phys Med Rehabil, 2010;91(3): 465-73.
12. Bruce JM, Hancock LM, Arnett P, Lynch S, Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition, J Behav Med, 2010;33(3):219-27.
13. Barker-Collo SL, Quality of life in multiple sclerosis: does information-processing speed have an independent effect?, Arch Clin Neuropsychol, 2006;21(2):167-74.
14. Kenealy PM, Beaumont GJ, Lintern T, Murrell R, Autobiographical memory, depression and quality of life in multiple sclerosis, J Clin Exp Neuropsychol, 2000;22(1):125-31.
15. Forn C, Belenguer A, Parcet-Ibars MA, Avila C, Information-processing speed is the primary deficit underlying the poor performance of multiple sclerosis patients in the Paced Auditory Serial Addition Test (PASAT), J Clin Exp Neuropsychol, 2008;30(7):789-96.
16. Parmenter BA, Shucard JL, Shucard DW, Information processing deficits in multiple sclerosis: a matter of complexity, J Int Neuropsychol Soc, 2007;13(3):417-23.
17. Parmenter BA, Shucard JL, Benedict RH, Shucard DW, Working memory deficits in multiple sclerosis: comparison between the n-back task and the Paced Auditory Serial Addition Test, J Int Neuropsychol Soc, 2006;12(5):677-87.
18. Benedict RH, Cookfair D, Gavett R, Gunther M, et al., Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS), J Int Neuropsychol Soc, 2006;12(4):549-58.
19. Rosti E, Hämäläinen P, Koivisto K, Hokkanen L, PASAT in detecting cognitive impairment in relapsing-remitting MS, Appl Neuropsychol, 2007;14(2):101-12.
20. Parmenter BA, Weinstock-Guttman B, Garg N, et al., Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test, Mult Scler, 2007;13(1):52-7.
21. Benedict RH, Duquin JA, Jurgensen S, et al., Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire, Mult Scler, 2008;14(7):940-46.
22. Rudick RA, Polman CH, Cohen JA, et al., Assessing disability progression with the Multiple Sclerosis Functional Composite, Mult Scler, 2009;15(8):984-97.
23. Brochet B, Deloire MS, Bonnet M, Set al., Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study, Mult Scler, 2008;14(9):1242-9.
24. Drake AS, Weinstock-Guttman B, Morrow SA, et al., Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test, Mult Scler, 2010;16(2):228-37.
25. Rosti-Otajärvi E, Hämäläinen P, Koivisto K, Hokkanen L, The reliability of the MSFC and its components, Acta Neurol Scand, 2008;117(6):421-7.
26. Rao SM, Neuropsychology of multiple sclerosis: a critical review, J Clin Exp Neuropsychol, 1986;8:503-42.
27. DeLuca J, Gaudino EA, Diamond BJ, et al., Acquisition and storage deficits in multiple sclerosis, J Clin Exp Neuropsychol, 1998;20(3):376-90.
28. Stegen S, Stepanov I, Cookfair D, et al., Validity of the California Verbal Learning Test-II in multiple sclerosis, Clin Neuropsychol, 2010;24(2):189-202.
29. Kenealy PM, Beaumont JG, Lintern TC, Murrell RC, Autobiographical memory in advanced multiple sclerosis: assessment of episodic and personal semantic memory across three time spans, J Int Neuropsychol Soc, 2002;8(6):855-60.
30. Drew M, Tippett LJ, Starkey NJ, Isler RB, Executive dysfunction and cognitive impairment in a large community-based sample with Multiple Sclerosis from New Zealand: a descriptive study, Arch Clin Neuropsychol, 2008;23(1):1-19.
31. Beatty WW, Fluency in multiple sclerosis: which measure is best?, Mult Scler, 2002;8(3):261-4.
32. Simioni S, Ruffieux C, Kleeberg J, et al., Progressive decline of decision-making performances during multiple sclerosis, J Int Neuropsychol Soc, 2009;15(2):291-5.
33. Rao SM, A manual for the Brief Repeatable Battery of neuropsychological tests in multiple sclerosis, Milwaukee, Wisconsin: Medical College of Wisconsin, 1990.
34. Portaccio E, Goretti B, Zipoli V, et al.; TuSCIMS Study Group. Reliability, practice effects, and change indices for Rao's Brief Repeatable Battery, Mult Scler, 2010;16(5):611-17.
35. Benedict RH, Fischer JS, Archibald CJ, et al., Minimal neuropsychological assessment of MS patients: a consensus approach, Clin Neuropsychol, 2002;16(3): 381-97.
36. Strober L, Englert J, Munschauer F, et al., Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS, Mult Scler, 2009;15(9):1077-84.
37. Portaccio E, Goretti B, Zipoli V, et al., A short version of Rao's Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis, Clin Neuropsychol, 2009;23:268-75.
38. Sørensen PS, Jønsson A, Mathiesen HK, et al., The relationship between MRI and PET changes and cognitive disturbances in MS, J Neurol Sci, 2006;245(1-2):99-102.
39. Sharma R, Fischer MT, Bauer J, et al., Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination, Acta Neuropathol, 2010 Jun 8 (Epub ahead of print).
40. Calabrese M, Agosta F, Rinaldi F, et al., Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis, Arch Neurol, 2009;66(9):1144-50.
41. Amato MP, Portaccio E, Goretti B, et al., Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis, Arch Neurol, 2007;64(8):1157-61.
42. Bellmann-Strobl J, Wuerfel J, et al., Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis, Neurology, 2009;73(20):1624-7.
43. Ghaffar O, Feinstein A, APOE epsilon4 and cognitive dysfunction in multiple sclerosis: a review, J Neuropsychiatry Clin Neurosci, 2010;22(2):155-65.
44. Amato MP, Portaccio E, Zipoli V, Are there protective treatments for cognitive decline in MS?, J Neurol Sci, 2006;245(1-2):183-6.
45. Fischer JS, Priore RL, Jacobs LD, et al., Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group, Ann Neurol, 2000;48(6): 885-92.
46. Kappos L, Freedman MS, Polman CH, et al., Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, Lancet Neurol, 2009;8:987-97.
47. Krupp LB, Christodoulou C, Melville P, et al., Donepezil improved memory in multiple sclerosis in a randomized clinical trial, Neurology, 2004;63:1579-85.
48. Cader S, Palace J, Matthews PM, Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis, J Psychopharmacol, 2009;23:686-96.
49. Cucurachi L, Immovilli P, Granella F, et al., Shortlatency afferent inhibition predicts verbal memory performance in patients with multiple sclerosis, J Neurol, 2008;255:1949-56.
50. Shaygannejad V, Janghorbani M, Ashtari F, et al., Effects of rivastigmine on memory and cognition in multiple sclerosis, Can J Neurol Sci, 2008;35:476-81.
51. Langdon DW, Cognitive rehabilitation in multiple sclerosis. In: Kesselring J, Comi G, Thompson A (eds), Multiple Sclerosis: Recovery of Function and Neurorehabilitation, Cambridge University Press, 2010.